Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Big Data Analytics for Prostate Radiotherapy.

Coates J, Souhami L, El Naqa I.

Front Oncol. 2016 Jun 14;6:149. doi: 10.3389/fonc.2016.00149. eCollection 2016. Review.

2.

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.

Rucinska M, Kieszkowska-Grudny A, Nawrocki S.

Strahlenther Onkol. 2016 Jul;192(7):449-57. doi: 10.1007/s00066-016-0971-2. Epub 2016 May 25.

3.

Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Abusamra A, Murshid E, Kushi H, Alkhateeb S, Al-Mansour M, Saadeddin A, Rabah D, Bazarbashi S, Alotaibi M, Alghamdi A, Alghamdi K, Alsharm A, Ahmad I.

Urol Ann. 2016 Apr-Jun;8(2):123-30. doi: 10.4103/0974-7796.176872. Review.

4.

Contemporary Management of Prostate Cancer.

Cotter K, Konety B, Ordonez MA.

F1000Res. 2016 Feb 16;5. pii: F1000 Faculty Rev-179. doi: 10.12688/f1000research.7183.1. eCollection 2016. Review.

5.
6.

Retreatment for prostate cancer with stereotactic body radiation therapy (SBRT): Feasible or foolhardy?

Arcangeli S, Agolli L, Donato V.

Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):425-9. doi: 10.1016/j.rpor.2014.08.001. Epub 2014 Sep 10. Review.

PMID:
26696782
7.

Biochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy.

Rakhsha A, Kashi AS, Mofid B, Houshyari M.

Electron Physician. 2015 Oct 19;7(6):1330-5. doi: 10.14661/1330. eCollection 2015 Oct.

8.

Prognostic Factors for Prostate Cancer Endpoints Following Biochemical Failure: A Review of the Literature.

Nguyen T, Boldt RG, Rodrigues G.

Cureus. 2015 Jan 5;7(1):e238. doi: 10.7759/cureus.238. eCollection 2015 Jan.

9.

Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer.

Wang LS, Murphy CT, Ruth K, Zaorsky NG, Smaldone MC, Sobczak ML, Kutikov A, Viterbo R, Horwitz EM.

Cancer. 2015 Sep 1;121(17):3010-7. doi: 10.1002/cncr.29472. Epub 2015 May 29.

10.

Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap.

Franca CA, Vieira SL, Carvalho AC, Bernabe AJ, Penna AB.

Radiol Bras. 2014 Mar-Apr;47(2):89-93. doi: 10.1590/S0100-39842014000200010.

11.

Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations.

Sanfilippo NJ, Cooper BT.

Am J Clin Exp Urol. 2014 Dec 25;2(4):286-93. eCollection 2014. Review.

12.

Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.

Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM.

J Clin Oncol. 2015 Feb 1;33(4):332-9. doi: 10.1200/JCO.2014.58.0662. Epub 2014 Dec 22.

13.

Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413.

Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M 3rd, Lawton CA, Sandler HM.

Cancer. 2015 Mar 15;121(6):844-52. doi: 10.1002/cncr.29146. Epub 2014 Nov 19.

14.

Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.

Alkhateeb S, Abusamra A, Rabah D, Alotaibi M, Mahmood R, Almansour M, Murshid E, Alsharm A, Alolayan A, Ahmad I, Alkushi H, Alghamdi A, Bazarbashi S.

Urol Ann. 2014 Oct;6(4):278-85. doi: 10.4103/0974-7796.140959.

15.

Predictive clinical indicators of biochemical progression in advanced prostate cancer patients receiving Leuplin depot as androgen deprivation therapy.

Chen CH, Hsieh JT, Huang KH, Pu YS, Chang HC.

PLoS One. 2014 Aug 14;9(8):e105091. doi: 10.1371/journal.pone.0105091. eCollection 2014.

16.

Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'.

Ahmed KA, Davis BJ, Mynderse LA, Slezak JM, Bergstralh EJ, Wilson TM, Choo CR.

Radiat Oncol. 2014 Jul 29;9:171. doi: 10.1186/1748-717X-9-171.

17.

Hypofractionation in prostate cancer: radiobiological basis and clinical appliance.

Mangoni M, Desideri I, Detti B, Bonomo P, Greto D, Paiar F, Simontacchi G, Meattini I, Scoccianti S, Masoni T, Ciabatti C, Turkaj A, Serni S, Minervini A, Gacci M, Carini M, Livi L.

Biomed Res Int. 2014;2014:781340. doi: 10.1155/2014/781340. Epub 2014 Apr 30. Review.

18.

Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.

Henríquez I, Sancho G, Hervás A, Guix B, Pera J, Gutierrez C, Abuchaibe O, Martínez-Monge R, Tormo A, Polo A.

Radiat Oncol. 2014 Apr 30;9:102. doi: 10.1186/1748-717X-9-102.

19.

Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis.

Zhu Z, Zhang J, Liu Y, Chen M, Guo P, Li K.

Br J Cancer. 2014 May 13;110(10):2396-404. doi: 10.1038/bjc.2014.197. Epub 2014 Apr 15.

20.

High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after radiotherapy.

Song W, Jung US, Suh YS, Jang HJ, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.

Korean J Urol. 2014 Feb;55(2):91-6. doi: 10.4111/kju.2014.55.2.91. Epub 2014 Feb 14.

Items per page

Supplemental Content

Write to the Help Desk